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Abstract
Background:  Drug-metabolizing enzymes play a role in chemical carcinogenesis through
enzymatic activation of procarcinogens to biologically reactive metabolites. The role of gene
polymorphisms of several cytochrome P450 enzymes in digestive cancer risk has been extensively
investigated. However, the drug-metabolizing enzymes with the broader substrate specificity,
CYP3A4 and CYP3A5, have not been analyzed so far. This study aims to examine associations
between common CYP3A4 and CYP3A5 polymorphisms and digestive cancer risk.
Methods: CYP3A4 and CYP3A5 genotypes were determined in 574 individuals including 178
patients with primary liver cancer, 82 patients with gastric cancer, 151 patients with colorectal
cancer, and 163 healthy individuals.
Results: The variant allele frequencies for patients with liver cancer, gastric cancer, colorectal
cancer and healthy controls, respectively, were: CYP3A4*1B, 4.8 % (95% C.I. 2.6–7.0), 3.7 % (0.8–
6.6) 4.3% (2.0–6.6) and 4.3% (2.1–6.5); CYP3A5*3, 91.8 % (93.0–97.4), 95.7% (92.6–98.8), 91.7%
(88.6–94.8) and 90.8% (87.7–93.9). The association between CYP3A4*1B and CYP3A5*3 variant
alleles did not significantly differ among patients and controls. No differences in genotypes, allele
frequencies, or association between variant alleles were observed with regard to gender, age at
diagnosis, tumour site or stage.
Conclusion: Common polymorphisms on CYP3A4 and CYP3A5 genes do not modify the risk of
developing digestive cancers in Western Europe.
Background
The identification of low penetrance genes able to
increase the risk of developing cancer could constitute a
major tool for the identification of individuals with inher-
itable altered susceptibility. In this regard, the role of
drug-metabolizing enzymes in cancer risk has been the
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object of several hundreds of studies performed over the
last decade [1]. The main hypothesis underlying the link
between drug-metabolizing enzymes and chemical car-
cinogenesis is based on the enzymatic activation of pro-
carcinogens to biologically reactive metabolites. These
reactive metabolites would interact with DNA, thereby
causing altered gene expression or function, and eventu-
ally carcinogenesis. The primary metabolism of a variety
of xenobiotic carcinogens is mainly mediated by cyto-
chrome P450 (CYP) enzymes belonging to the CYP 1, 2 or
3 families, which together comprise 25 different isoen-
zymes. Among them, the most relevant are CYP1A1,
CYP1A2, CYP1B1, CYP2E1, CYP3A4 and CYP3A5 [2-4].
Most of the latter enzymes are polymorphic, mutated alle-
les causing abolished, reduced or altered enzyme activity.
To date, several studies have focused on the role of gene
polymorphisms or enzyme activities of CYP1A1 [5-11],
CYP1A2 [7,12-14], CYP1B1 [7,15] and CYP2E1 [6,16-19]
in digestive cancer risk. Nevertheless, the impact on cancer
risk of polymorphisms of the CYP enzymes with the
broader substrate specificity, namely CYP3A4 and
CYP3A5, has not been analyzed in detail so far.
CYP3A4 and CYP3A5 enzymes are the major enzymes for
drug metabolism in adults [20], both enzymes making up
nearly 30% of the total CYP enzymes expressed in the
human liver [21]. Since no individualized quantification
of CYP3A4 and CYP3A5 in vivo is presently possible due
to a wide substrate specificity overlap, the joined enzyme
activities are designated as CYP3A [22]. Both CYP3A4 and
CYP3A5 are expressed in liver, stomach, colorectal epithe-
lium and in colorectal cancer tissue [23-26], although
large interindividual differences exist in the expression of
both enzymes [27-29]. Besides a local effect of the enzyme
activities in the metabolism of carcinogens, CYP3A4/5-
dependent metabolism in the proximal intestine is likely
to affect the luminal or vascular delivery of carcinogenic
molecules to the liver or the colon.
These facts provide a plausible hypothesis for organ-spe-
cific dietary procarcinogen activation and therefore to
digestive cancer risk. The hypothesis that justify the
present study is based in the fact that CYP3A4 and
CYP3A5 enzyme activities are involved in the activation of
several procarcinogens, including aflatoxin B1 stergmato-
cystin, food-derived heterocyclic amines, alpha-hydrox-
ytamoxifen and N'-nitrosonornicotine, and that both
enzymes are expressed to a high level in the digestive tract
[27,30-36]. Thus, it can be hypothesized that genetic dif-
ferences causing variability in the regulation, expression
or activity of CYP3A enzymes would be relevant factors
modifying cancer susceptibility or clinical outcome. These
allele-disease associations have already been shown for
CYP3A gene polymorphisms and prostate, breast and
lung cancer [37-43], albeit with controversial results.
Although CYP3A4 and CYP3A5 play a relevant biological
role in liver and in gut epithelium, no studies have
addressed whether polymorphism of these enzymes are
related to digestive cancer risk, probably because variant
alleles for the corresponding genes have just recently been
described. In this regard, novel findings show that
CYP3A5  genotypes leading to high enzyme activity are
related to oesophageal cancer [44]. However the interac-
tion of CYP3A4 and CYP3A5 gene polymorphisms and
the risk of developing the major digestive cancers such as
liver, stomach or colorectal cancers remain unexplored.
This study aims to analyze such interaction.
Methods
The study group consisted of 411 unrelated patients with
digestive cancers, including 178 patients with primary
liver cancer, 82 patients with gastric cancer and 151
patients with colorectal cancer, and 163 healthy subjects.
Table I shows a summary of the study groups included in
the study. All the participants were white Spanish individ-
uals, living in the same areas as the patients (Madrid and
surrounding areas), and were included in the study after
giving informed written consent. All the patients diag-
nosed with liver, stomach or colorectal cancer that
attended the collaborating Services of the selected Hospi-
tals were included in the study. The diagnosis was based
on histology analyses of endoscopic biopsies and/or sur-
gical resection specimens. Data regarding known previous
digestive diseases, alcohol and tobacco consumption,
serum tests for hepatitis B and C virus and other diseases
were collected. Heavy drinkers were defined as individuals
drinking more than 50 g of alcohol per day.
All the patients were requested to participate in the study,
and all of them agreed to do so. Control samples were
obtained from medical students, University and Hospital
staff. A medical examination was made to identify sub-
jects in good health. Over 95% of the healthy subjects
requested agreed to participate in the study. The protocol
was approved by the Ethics Committee of the San Carlos
University Hospital, Madrid. A possible confounding fac-
tor in the present study is that, within a study group, the
frequency of individuals carrying a determined variant
allele may change with age in the event that the presence
of such allele would be related to severe diseases. If a
determined genotype has a "protecting effect" against any
disease, it may be expected that in populations composed
of older subjects there is an increased frequency of such a
protecting genotype. Therefore we included within the
control group a selected subgroup of 41 healthy subjects
with ages ranging from 90 to 95 years [45]. The analysis of
the CYP3A4 and CYP3A5 genotype indicates frequencies
for genotypes that were identical to those of younger
healthy subjects. The frequencies for CYP3A4*1B  and
CYP3A5*3 alleles were similar for younger and older con-BMC Cancer 2007, 7:118 http://www.biomedcentral.com/1471-2407/7/118
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trols (see Results section). 4.33% and 90.7% for younger
controls and 4.18 and 91.2% for older controls. Another
possible confounder is related to the fact that control sub-
jects are highly educated people, and differences in life-
style as compared to cancer patients may be expected.
Since digestive cancers are partly related to diet, these
changes in lifestyle may be relevant. However, it should be
stated that patients and controls were interviewed to
assure that diet and lifestyle do no differ between patients
and control subjects.
Blood samples from all participants were stored at -80°C
until analysis. The genomic DNA was prepared from
peripheral leucocytes, and dissolved in sterile 10 mM Tris-
HCl, pH 8.0, 1 mM ethylenediaminetetraacetic acid, at a
final concentration of 400 to 600 mg per ml. DNA sam-
ples were purified according standard procedures [46] and
stored at 4°C in sterile plastic vials.
The analyses for the CYP3A4*1B and CYP3A5*3 gene var-
iants were carried out by amplification-restriction proce-
dures as described elsewhere [47,48]. These allelic variants
were analyzed instead of others because these are com-
mon variants that cause functional changes. [47,48].
Statistical analysis
The study was designed taking into consideration the
expected frequency of individuals expressing CYP3A5, i.e.
carrying at least one CYP3A5*1 allele, which represents
13% of the Caucasian population [20]. The design per-
mits the identification as statistically significant of a 1.7-
fold increase or a 2-fold decrease in the frequency for
CYP3A5 expressers among cancer patients. Statistical
power was evaluated with a genetic model to analyze the
frequency for carriers of the disease gene with an RR value
= 2.5 (α = 0.05). The power calculated for associations
with cancer risk for the presence of the CYP3A4*1B and
CYP3A5*3 alleles is 90.2% and 99.3% for liver cancer,
74.5% and 93.9% for gastric cancer and 87.7% and 98.8%
for colorectal cancer, respectively. The intergroup compar-
ison values were calculated by using the statistical package
SPSS 11.0.1. (SPSS Inc. Chicago, Ill, USA). The Chi-square
(X2) test was used for comparison of genotype frequencies
and association of CYP3A4 and CYP3A5 variant alleles,
unless the conditions for the application of this test were
not adequate. In such cases, Fisher's exact test was used to
calculate the p value.
Results
Seven different combinations of CYP3A4  and  CYP3A5
genotypes were identified in the study groups. The sum-
mary of the genotypes is shown in Table 2. The compari-
son of genotype frequencies among digestive cancer
patients and healthy controls indicates a similar genotype
frequency across the study groups. No statistically signifi-
cant differences were observed. The variant allele frequen-
cies, as calculated from genotypes shown in Table 2, were
almost identical for all study groups: CYP3A4*1B  was
present with allele frequencies of 4.8 (95% CI 2.6–6.9),
3.7 (95% CI 0.8–6.5) and 4.3% (95% CI 2.0–6.6) for
liver, stomach and colorectal cancer patients, respectively,
and 4.3% (2.1–6.5) for healthy individuals. The allele fre-
quencies for CYP3A5*3 were 91.9 (95% CI 89.0–94.7),
95.7 (95% CI 92.6–98.8), and 91.7% (95% CI 88.6–94.8)
for liver, stomach and colorectal cancer patients, respec-
tively, and 90.8% (95% CI 87.7–93.9) among healthy
individuals. No statistically significant differences in the
allele frequencies were observed, although the frequency
for the functional CYP3A5*1 allele among stomach cancer
patients is lower (approximately 50%) than those
observed for the rest of the study groups (p = 0.051 as
compared to healthy subjects).
Both  CYP3A4  and  CYP3A5  genotypes were at Hardy-
Weinberg's equilibrium among cases and controls and
variant allele frequencies are consistent with those
reported for both, European and American Caucasians
[20,49]. Regarding the association between the
CYP3A4*1B  and  CYP3A5*1  alleles, the proportion of
individuals carrying both variants is much higher for all
the study groups (6.7%, 6.1% and 4.6% for liver, gastric
or colorectal cancer patients and 7.4% for control sub-
jects) than expected from a random association of these
alleles (0.3 to 0.8% of individuals, as calculated from
actual allele frequencies in the study groups). These find-
ings are in agreement with a previous study that reports
such an SNP association in another Caucasian population
with a frequency of 7.1%. [22,43]. Among patients, age at
diagnosis was similar in all subgroups of patients, and this
parameter was not related to the genotypes. Regarding
Table 1: Summary of the study groups.
NO MALES FEMALES MEAN AGE (SD; RANGE)
Liver cancer 178 145 33 66.1 (9.8; 20–88)
Gastric cancer 82 54 28 67.7 (13.9; 31–99)
Colorectal cancer 151 82 69 66.3 (11.2; 33–89)
Healthy subjects 163 111 52 46.3 (12.7; 21–95)
No: number of subjectsBMC Cancer 2007, 7:118 http://www.biomedcentral.com/1471-2407/7/118
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control subjects, the frequencies for CYP3A4*1B  and
CYP3A5*3  alleles were 4.33% and 90.7% for younger
controls and 4.18 and 91.2% for older controls. Gender,
previous surgical therapy or chemotherapy, alcohol abuse
or tobacco use did not influence the distribution of the
polymorphisms studied among patients. Among liver
cancer patients no differences in the distribution of poly-
morphisms regarding chronic infection with hepatitis B or
C virus were observed. Among gastric cancer patients no
statistically significant differences were observed regard-
ing the anatomical site of the tumour. In contrast, signifi-
cant differences showing an increase in the frequency of
carriers of the CYP3A4*1A  plus  CYP3A5*3  haplotype,
were observed among patients with intestinal-type gastric
cancer as compared to healthy controls (95.3% versus
82.8%, p < 0.05).
Colorectal cancer patients were divided into three sub-
groups according to the anatomical site of the tumour
(non-sigmoid colon, sigmoid colon and rectum), because
differences in the association of other polymorphisms of
drug-metabolizing enzymes related to tumour site have
been reported [50,51]. The results are summarized in
Table 3. An excess of patients with non-sigmoid colon
cancer carrying the combined genotype CYP3A4*1A/*1B
plus CYP3A5*3/*3 was observed as compared to healthy
subjects (Chi-square = 10.3, p = 0.0015, non significant in
multiple comparison analyses) With regard to allele fre-
quencies, CYP3A4*1B allele frequency was 6.6%, 5.9%
and 1% and CYP3A5*3 frequency was 91.1%, 90.1% and
93.6% among patients with non-sigmoid colon, sigmoid
colon and rectum, respectively. The proportion of individ-
uals carrying CYP3A4*1B  and  CYP3A5*1  alleles was
13.3%, 9.8% and 1.8% for patients with non-sigmoid
colon, sigmoid colon and rectum, respectively. None of
these differences were statistically significant. No differ-
ences regarding Dukes' stage of the tumour were observed.
Discussion
Metabolism related to CYP enzymes differ between organs
and tissues, and therefore it is expected that tissue specifi-
city towards cancer-inducing substances is related to site-
specific expression of xenobiotic-metabolizing enzymes.
Digestive cancers are strongly related to dietary factors,
and mechanisms involving the interaction of such dietary
factors with determined polymorphisms of xenobiotic-
metabolizing enzymes have been proposed [10]. Most of
the CYP genes expressed in human gut and liver, namely
CYP1A1, CYP1A2, CYP1B1, CYP3A4 and CYP3A5 [25], are
of great relevance for carcinogen activation. With the
exception of CYP3A4 and CYP3A5, all genes coding for
these enzymes have been studied with regard to digestive
cancer risk [1]. This study was aimed to fill the gap in the
present knowledge of the putative role of polymorphisms
of the two remaining relevant CYP enzymes in the diges-
tive tract.
CYP3A enzyme activity shows interindividual variability
due to the combined effect of genetics and interaction
with drugs or environmental chemicals [22]. Both
CYP3A4 and CYP3A5 genes are polymorphic and several
variant alleles have been described for either the CYP3A4
or the CYP3A5 gene (for an updated list of alleles, see
[52]). Only two variant alleles that are at linkage disequi-
librium, namely CYP3A4*1B and CYP3A5*3 are common
across diverse ethnic populations and have functional rel-
evance. Other variant alleles are either extremely rare or
irrelevant for enzyme activity [20], and therefore they
were not analyzed in this study.
Present evidences indicate that CYP3A4*1B  and
CYP3A5*3 are functional polymorphisms in vivo. Regard-
ing CYP3A4*1B, it seems to modify the ability to metabo-
lize some CYP3A substrates, such as quinine [53],
although it does not influence the metabolism of other
substrates such as midazolam or dextromethorphan
[49,54]. CYP3A5*3 is the commonest CYP3A5 allele and
is associated with severely decreased enzyme activity [20].
The present study provides novel findings on the putative
role of CYP3A4 and CYP3A5 polymorphisms in digestive
cancer risk. In spite of the presence of CYP3A enzyme
activities in gut and liver, and of the relevant role of such
enzyme activities in carcinogen activation, our results do
not support a major link between common CYP3A4 and
CYP3A5 polymorphisms and digestive cancer risk. Never-
Table 2: CYP3A4 and CYP3A5 genotypes in digestive cancer patients and healthy control individuals.
CYP3A4 CYP3A5 Liver cancer
N (Frequency; 95% C.I.)
Stomach cancer
N (Frequency; 95% C.I.)
Colorectal cancer
N (Frequency; 95% C.I.)
Control subjects
N (Frequency; 95% C.I.)
*1A/*1A *3/*3 144 (80.9; 75.1–86.7) 74 (90.2; 83.8–96.7) 121 (80.1; 73.8–86.5) 134 (82.2; 76.4–88.1)
*1A/*1A *1/*3 17 (9.6; 5.2–13.9) 2 (2.4; 0–5.8) 18 (11.9; 6.8–17.1) 14 (8.6; 4.3–12.9)
*1A/*1A *1/*1 0 0 0 1 (0.6; 0–1.8)
*1A/*1B *3/*3 5 (2.8; 0.4–5.2) 1 (1.2; 0–3.6) 5 (3.3; 0.5–6.2) 1 (0.6; 0–1.8)
*1A/*1B *1/*3 12 (6.7; 3.1–10.4) 5 (6.1; 0.9–11.3) 6 (4.0; 0.9–7.1) 12 (7.4; 3.3–11.4)
*1A/*1B *1/*1 0 0 0 1 (0.6; 0–1.8)
*1B/*1B *1/*3 0 0 1 (0.7; 0–2.0) 0BMC Cancer 2007, 7:118 http://www.biomedcentral.com/1471-2407/7/118
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theless the possibility for a low to moderate effect for
these polymorphisms especially in the smallest group,
stomach cancer, can not be ruled out. Minor differences in
the frequencies for individuals carrying the CYP3A4*1A
plus CYP3A5*3 haplotypes were observed in some sub-
groups of gastric or colon cancer, as compared to healthy
subjects, with p values under 0.05. These differences can-
not be considered statistically significant in multiple-
comparison analyses, and do not seem to have a relevant
clinical impact. However, this is a topic that deserves
investigation and further studies should focus on the role
of such polymorphisms in liver, gastric or colorectal can-
cer in populations with extreme incidence rates of these
cancers.
Conclusion
Taking together the findings reported in the present study,
it can be concluded that common polymorphisms of
CYP3A enzymes with functional relevance are not signifi-
cant factors in digestive carcinogenesis in Western Europe.
This is in contrast to other human cancers that are related
to such polymorphisms. Since human guts are the pri-
mary tissues that have contact with dietary carcinogens, it
is intriguing that digestive cancer risk is not modified by
genetic factors that are related to other human cancers
such as prostate, breast or lung, thus reinforcing the
hypothesis that the association of CYP3A polymorphisms
with prostate or breast cancer are related to endogenous
substances rather than xenobiotics carcinogens [37-43].
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